Futura Medical PLC (LON:FUM) has been reiterated to Corporate in a statement by N+1 Singer earlier today.
- Updated: October 12, 2016
Boasting a price of 65.00GBX, Futura Medical PLC (LON:FUM) traded -0.23% lower on the day. With the last close up 121.15% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Futura Medical PLC has recorded a 50-day average of 56.33GBX and a two hundred day average of 29.32GBX. Volume of trade was down over the average, with 32,231 shares of FUM changing hands under the typical 776,919
N+1 Singer has reiterated Futura Medical PLC (LON:FUM) to Corporate in a statement released on 10/13/2016.
With a total market value of 0 GBX, Futura Medical PLC has 52 week low of 14.31GBX and a 52 week high of 95.60GBX .
Brief Synopsis On Futura Medical PLC (LON:FUM)
Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.